Table 1.
Overview of the patient cohort, follow-up, and tumor markers
| Patient | Gender | Primary tumor | Cycles/activity (GBq) | ChrAinitial (ng/ml) | ChrApost (ng/ml) | Change ChrA (%) | RECIST | Course of follow-up |
|---|---|---|---|---|---|---|---|---|
| 1 | M | G-NET | 4/4 Y+18 Lu | 10 | n.e.a.b. | −100 | CR >27 months; last ChrA 6.3 | |
| 2 | F | P-NET | 3/12 Y+4 Lu | 50 | 23.1 | −53.8 | −57 | SD within partial remission >13 months; last ChrA 17.6 |
| 3 | F | P-NET | 3/12.5 Y+4 Lu | 3069 | 302 | −90.16 | −50.69 | PD (bone) after 12 months (ChrA 202.8); SAx; PD (liver) after 18 months; last ChrA 4158; CTx |
| 4 | F | P-NET | 2/8 Y+8 Lu | 120 | 48.2 | −59.83 | −50 | SD within partial remission >13 months; last ChrA 97.4 |
| 5 | M | P-NET | 3/12 Y+12 Lu | 33 | 15.9 | −51.82 | −48.56 | SD within partial remission >25 months; last ChrA 18.5 |
| 6 | F | P-NET | 4/22 Y+12 Lu | 131 | 24.5 | −81.3 | −43.98 | Further PR for 23 months; re-evaluation: downstaged to surgery; last ChrA <5 |
| 7 | F | P-NET | 5/18 Y+14 Lu | 133.9 | 13.3 | −90.07 | −42.81 | SD within partial remission >25 months; last ChrA 17.9 |
| 8 | F | P-NET | 4/16 Y+16 Lu | 41.5 | 38.2 | −7.95 | −40.07 | SD within partial remission >26 months; last ChrA 41.7 |
| 9 | F | P-NET | 3/4 Y+24 Lu | 86.8 | 32.1 | −63.02 | −35 | SD within partial remission >22 months under SAx; last ChrA 64.7 |
| 10 | M | CUP-NET | 2/14 Y+2 Lu | 171.5 | 64.5 | −62.39 | −24.29 | SD >15 months last ChrA 50.2 |
| 11 | F | Jejunum | 2/8 Y+8 Lu | 45.4 | 45.7 | 0.66 | −5.33 | SD >18; SIRT due to recurrent diarrhea; SD > 5 months; last ChrA 25.1 |
| 12 | M | Jejunum | 2/6 Y+6.4 Lu | 330 | 385 | 16.67 | −4.55 | SD >19; last ChrA 221.5 |
| 13 | M | Jejunum | 2/6 Y+4 Lu | 1100 | 429 | −61 | 0 | SD >13; last ChrA 130.8; SAx |
| 14 | F | G-NET | 4/16 Y+13 Lu | 902 | 1462 | 62.08 | 3.43 | PD (bone) after 11 months; ChrA 2651; CTx; death after 5 months |
| 15 | M | Illeocoecal | 3/12 Y+10.4 Lu | 95.9 | 102 | 6.36 | 7.7 | PD (liver) after 12 months; 3 additional cycles i.a. DOTA- TOC; PD (liver) after >6 months; last ChrA 370.7 |
Cycles, number of treatments; activity, cumulative prescribed activity; Y, Yttrium-90; Lu, Lutetium-177; ChrA, chromogranin A; M, male; F, female; P-NET, pancreatic neuroendocrine tumor; G-NET, gastric neuroendocrine tumor; CUP-NET, neuroendocrine tumor of unknown primary; PD, progressive disease; SD, stable disease; SAx, treatment with somatostatin analogues; CTx, chemotherapy; SIRT, radioembolization; n.e.a.b., not elevated at baseline.